Antimicrobial Susceptibility Testing of Cefepime Enmetazobactam Against Multidrug Resistant Pathogens

Abstract

Multidrug-resistant (MDR) bacteria are becoming more common, which is a serious threat to public health and makes treating a variety of illnesses more difficult. Pathogens that show resistance to several kinds of antibiotics, such as carbapenems, extended-spectrum β-lactams, and other widely used medicines, are among the most alarming. The purpose of this study is to assess the antimicrobial susceptibility of a novel β-lactam/β-lactamase inhibitor combination, cefepime-enmetazobactam, against a group of MDR pathogens. The minimum inhibitory concentrations (MICs) of cefepime-enmetazobactam against a variety of clinical isolates of MDR pathogens, such as Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii, and other clinically significant resistant organisms, were found using conventional broth microdilution techniques. The findings show that cefepime-enmetazobactam has strong in vitro action against a variety of MDR bacteria, including those that produce carbapenemases and extended-spectrum β-lactamases (ESBLs). It was discovered to be very efficient against A. baumannii and K. pneumoniae, which are frequently linked to serious hospital-acquired infections. According to these results, cefepime-enmetazobactam is a potentially effective treatment for infections brought on by MDR microorganisms. To properly evaluate its safety, effectiveness, and possible role in controlling resistant infections in hospital settings, more research—including clinical trials—is required.